842P - Exploring the association of side-effects with depression in patients with chronic lymphocytic leukemia who have received treatment: An analysis of the lymphoma coalition’s 2022 global patient survey

Background

Symptoms of depression are highly prevalent amongst patients with cancer. We sought to identify which treatment related side-effects were associated with an increased incidence of depression in patients with chronic lymphocytic leukemia (CLL).

Methods

A global survey was deployed in 2022 to gather patient reported outcomes and patient reported experience measures from a cross-section of patients with lymphoma and CLL. The incidence of 32 side-effects were cross-tabulated with reports of depression amongst patients with CLL who received treatment.

Results

Of the 611 respondents who received treatment and disclosed whether they suffered from depressive symptoms, 21% (N = 131) reported experiencing depression. The entire sample had a median age of 66 years and 46% were female. No significant differences in age or biological sex were found. The following side-effects were significantly associated with increased reports of depression: changes in sleep patterns (p<0.0001); pain (p<0.0001), lack of concentration (p<0.0001), inability to multitask (p<0.0001); respiratory problems (p<0.0001); loss of memory (p<0.0001); peripheral neuropathy (p<0.0001); sexual and intimacy problems (p<0.0001); eyesight issues (p = 0.0002); headaches (p = 0.0002); infusion reaction (p = 0.0006); neurological effects (p = 0.0007), fatigue (p = 0.0007); changes in taste and smell (p = 0.0008); constipation (p = 0.001); easy bruising and bleeding (p = 0.002); dental issues (p = 0.002); osteoporosis (p = 0.002); mouth and throat symptoms (p = 0.01); kidney problems (0.01); skin, hair and nail problems (p = 0.02); infertility (p = 0.02); and diarrhea (0.03).

Conclusions

The large breadth of side-effects (N = 23) that are associated with increased incidence of depression suggests that interventions to mitigate side-effects are likely to have unanticipated benefits for the health-related quality of life for patients with CLL. Implementation of assessment methods to ensure patients disclose all side effects and are provided with the appropriate supportive care will reduce comorbidities and yield improved outcomes for patients with CLL.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

AbbVie, BMS, Pharmacyclics, Roche.

Disclosure

All authors have declared no conflicts of interest.